Principia Biopharma Inc (PRNB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Principia Biopharma Inc (PRNB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11223
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Principia Biopharma Inc (Principia Biopharma) is a clinical stage biopharmaceutical company that designs and develops oral small molecule drug therapies for immune disorders and cancer. The company, through its proprietary Tailored Covalency platform, develops a portfolio of drug candidates such as PRN1008, PRN2246 and PRN1371. PRN1008, under Phase 3 initiation for pemphigus vulgaris, an orphan autoimmune disease, and Phase 2 trial for immune thrombocytopenic purpura, is a reversible covalent BTK inhibitor. PRN2246, which crosses the blood-brain barrier, is under Phase 1 clinical trial as an oral therapy to treat autoimmunity and neuro-inflammatory diseases. The PRN1371 candidate, under Phase 1 trial, is used in treating bladder cancer and solid tumors. Principia Biopharma is headquartered in South San Francisco, California, the US.

Principia Biopharma Inc (PRNB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Principia Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Principia Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Principia Biopharma Raises USD15.2 Million in Venture Funding 11
Principia Biopharma Raises US$50 Million In Series B Venture Financing 12
Principia Biopharma Raises Additional US$13 Million In Series A Financing 14
Private Equity 16
Principia Biopharma Raises USD50 Million in Offering of Series C Preferred Stock 16
Partnerships 17
AbbVie and Principia Biopharma Enter into Agreement 17
Guardant Health Enters into Agreement with Principia Biopharma 18
Licensing Agreements 19
Sanofi Amends Licensing Agreement with Principia Biopharma 19
Equity Offering 20
Principia Biopharma Raises USD122.2 Million in IPO of Shares 20
Principia Biopharma Inc – Key Competitors 22
Principia Biopharma Inc – Key Employees 23
Principia Biopharma Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Nov 06, 2018: Principia Biopharma reports third quarter financial results 25
Corporate Communications 26
Oct 24, 2018: Principia Biopharma appoints Dolca Thomas, M.D. as Chief Medical Officer 26
Clinical Trials 27
Jul 26, 2018: Principia confirms human CNS exposure and good tolerability of oral BTK inhibitor PRN2246 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Principia Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Principia Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Principia Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Principia Biopharma Raises USD15.2 Million in Venture Funding 11
Principia Biopharma Raises US$50 Million In Series B Venture Financing 12
Principia Biopharma Raises Additional US$13 Million In Series A Financing 14
Principia Biopharma Raises USD50 Million in Offering of Series C Preferred Stock 16
AbbVie and Principia Biopharma Enter into Agreement 17
Guardant Health Enters into Agreement with Principia Biopharma 18
Sanofi Amends Licensing Agreement with Principia Biopharma 19
Principia Biopharma Raises USD122.2 Million in IPO of Shares 20
Principia Biopharma Inc, Key Competitors 22
Principia Biopharma Inc, Key Employees 23

List of Figures
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Principia Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Principia Biopharma Inc (PRNB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Flint Hills Resources LLC:企業の戦略的SWOT分析
    Flint Hills Resources LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Brunswick Corporation (BC):企業の財務・戦略的SWOT分析
    Brunswick Corporation (BC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Cesca Therapeutics Inc (KOOL):製品パイプライン分析
    Summary Cesca Therapeutics Inc (Cesca) researches, develops, and commercializes cell based therapeutics for applications in regenerative medicine. Its proprietary technology platform, PXP is used to develop autologous cell-based therapies for the in the vascular and orthopedic markets. Its device di …
  • Lebara Group:企業の戦略的SWOT分析
    Lebara Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Response Biomedical Corp:企業の戦略的SWOT分析
    Response Biomedical Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Midatech Pharma US Inc-医療機器分野:企業M&A・提携分析
    Summary Midatech Pharma US Inc (Midatech Pharma), formerly DARA BioSciences, Inc., is a pharmaceutical company which focuses on the development and commercialization of cancer treatment and supportive care products. The company’s product portfolio includes Soltamox for the treatment and prevention o …
  • Vitol Holding BV:企業の戦略的SWOT分析
    Vitol Holding BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • BioGaia AB (BIOG B):企業の財務・戦略的SWOT分析
    BioGaia AB (BIOG B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Mangalam Drugs and Organics Ltd (MANGALAM):企業の財務・戦略的SWOT分析
    Summary Mangalam Drugs and Organics Ltd (MDOL) carries out manufacturing and supplying of specialty chemicals, intermediates, and active pharmaceutical ingredients. The company's active pharmaceutical ingredients include amodiaquine HCl, bisoprolol fumarate, artemether, dihydroartemisinin, hydroxy c …
  • Deutsche Borse Ag:企業の戦略・SWOT・財務分析
    Deutsche Borse Ag - Strategy, SWOT and Corporate Finance Report Summary Deutsche Borse Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Realtek Semiconductor Corp. (2379):企業の財務・戦略的SWOT分析
    Realtek Semiconductor Corp. (2379) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Arabtec Holding:企業の戦略・SWOT・財務情報
    Arabtec Holding - Strategy, SWOT and Corporate Finance Report Summary Arabtec Holding - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Viterra Inc.:企業の戦略・SWOT・財務情報
    Viterra Inc. - Strategy, SWOT and Corporate Finance Report Summary Viterra Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • FP Corporation:企業の戦略・SWOT・財務情報
    FP Corporation - Strategy, SWOT and Corporate Finance Report Summary FP Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Zoo Digital Group plc (ZOO):企業の財務・戦略的SWOT分析
    Summary Zoo Digital Group Plc (ZOO) is a technology company that offers localization and media production services. The company offers services such as subtitling, captioning, dubbing and digital distribution. Its activities include providing a range of services to allow television and movie content …
  • Empire Electric Association Inc:企業の戦略的SWOT分析
    Empire Electric Association Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Daewoo Shipbuilding & Marine Engineering Co Ltd:企業の戦略・SWOT・財務分析
    Daewoo Shipbuilding & Marine Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Daewoo Shipbuilding & Marine Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • UCB SA (UCB):企業の財務・戦略的SWOT分析
    UCB SA (UCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • ManpowerGroup Inc (MAN):企業の財務・戦略的SWOT分析
    ManpowerGroup Inc (MAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • BioCryst Pharmaceuticals Inc (BCRX):企業の財務・戦略的SWOT分析
    BioCryst Pharmaceuticals Inc (BCRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆